ConductScience.org, home

Paper39272178

In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma.

Krug A and 7 others. J Exp Clin Cancer Res, 2024. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma. Papers, record 39272178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39272178

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vivo CAR T cell therapy against angioimmunoblastic T cell lymphoma.
PubMed
Journal
J Exp Clin Cancer Res
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
1.75, provisional
iCite
Revised in PubMed
2024-09-16
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Krug AAdrien
2Saidane AAymen
3Martinello CChiara
4Fusil FFloriane
5Michels AAlexander
6Buchholz CJChristian J
7Ricci JEJean-Ehrland
8Verhoeyen EElshttps://orcid.org/0000-0001-9224-5491

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, Chimeric AntigenMajor topic
Immunotherapy, AdoptiveMajor topic
Lymphoma, T-CellMajor topic
Disease Models, AnimalMajor topic
Animals
Mice
Humans
Immunoblastic Lymphadenopathy
CD8-Positive T-Lymphocytes
Cell Line, Tumor

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
ANR-16-CE16-0024-01Agence Nationale de la RecherchePubMed
GET-INH2020 Marie Skłodowska-Curie ActionsPubMed
PhD followshipMinistère de l'Enseignement Supérieur et de la RecherchePubMed

Source PubMed

Download CSV of grants

References64

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129398449RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.Cancer Cell2018https://conductscience.org/library/papers/29398449PubMed
227281338Receptor-Targeted Nipah Virus Glycoproteins Improve Cell-Type Selective Gene Delivery and Reveal a Preference for Membrane-Proximal Cell Attachment.PLoS Pathog2016https://conductscience.org/library/papers/27281338PubMed
329769264RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice.Blood2018https://conductscience.org/library/papers/29769264PubMed
432485137In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes.Mol Ther2020https://conductscience.org/library/papers/32485137PubMed
531118293Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates.Sci Transl Med2019https://conductscience.org/library/papers/31118293PubMed
625794369Cutaneous manifestations of angioimmunoblastic T-cell lymphoma: clinical and pathological characteristics.Am J Dermatopathol2015https://conductscience.org/library/papers/25794369PubMed
728115369Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.Blood2017https://conductscience.org/library/papers/28115369PubMed
817873758Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients.Medicine (Baltimore)2007https://conductscience.org/library/papers/17873758PubMed
920453843PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells.Nat Immunol2010https://conductscience.org/library/papers/20453843PubMed
1032796826New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP.Oncogenesis2020https://conductscience.org/library/papers/32796826PubMed
1130224381In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome.EMBO Mol Med2018https://conductscience.org/library/papers/30224381PubMed
1230275568Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.Nat Med2018https://conductscience.org/library/papers/30275568PubMed
1326232436Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.J Immunol2015https://conductscience.org/library/papers/26232436PubMed
1434729380Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8.Mol Ther Methods Clin Dev2021https://conductscience.org/library/papers/34729380PubMed
1536736318IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment.Cancer Cell2023https://conductscience.org/library/papers/36736318PubMed
1633846629Genetic in vivo engineering of human T lymphocytes in mouse models.Nat Protoc2021https://conductscience.org/library/papers/33846629PubMed
1725692700ICOS coreceptor signaling inactivates the transcription factor FOXO1 to promote Tfh cell differentiation.Immunity2015https://conductscience.org/library/papers/25692700PubMed
1837866783Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.Transplant Cell Ther2024https://conductscience.org/library/papers/37866783PubMed
1927269947Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.J Clin Oncol2016https://conductscience.org/library/papers/27269947PubMed
2019236377Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.Br J Haematol2009https://conductscience.org/library/papers/19236377PubMed

See all 64 referencesDownload CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
42942823Unraveling Vulnerabilities and Pathways Responsible for AITL Malignancy to Improve Patients' Treatment.Pharmaceutics2026https://conductscience.org/library/papers/42942823PubMed
42802858Advancing In Vivo Chimeric Antigen Receptor T-Cell Engineering to Accelerate Clinical Translation.MedComm (2020)2026https://conductscience.org/library/papers/42802858PubMed
42502508Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector for in vivo CD19-directed CAR-T therapy.Mol Ther Adv2026https://conductscience.org/library/papers/42502508PubMed
42170676Engineering precision oncology: Targeting tumors and immune cells with lentiviral vectors.Mol Ther Oncol2026https://conductscience.org/library/papers/42170676PubMed
42065060In Vivo CAR-T Therapy for Cancer Treatment: Mechanisms, Technological Advances, and Clinical Translation.Oncol Res2026https://conductscience.org/library/papers/42065060PubMed
41575553Radiotherapy in addition to systemic therapy reduces the early mortality of angioimmunoblastic T-cell lymphoma.Ann Hematol2026https://conductscience.org/library/papers/41575553PubMed
41535417Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity.Ann Hematol2026https://conductscience.org/library/papers/41535417PubMed
41261423In vivo CAR cell therapy: from bench to bedside.J Hematol Oncol2025https://conductscience.org/library/papers/41261423PubMed
41079670Revolution in Cell Therapy: In Vivo Chimeric-Antigen-Receptor-T-Cell Therapy Breakthroughs and Promises for the Future.Research (Wash D C)2025https://conductscience.org/library/papers/41079670PubMed
41028170In vivo chimeric antigen receptor (CAR)-T cell therapy.Nat Rev Drug Discov2026https://conductscience.org/library/papers/41028170PubMed
41016988Cancer gene therapy: historical perspectives, current applications, and future directions.Funct Integr Genomics2025https://conductscience.org/library/papers/41016988PubMed
40560424Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advances.Clin Exp Med2025https://conductscience.org/library/papers/40560424PubMed
40346022Scavenging Reactive Oxygen Species by Cerium Oxide Nanoparticles Prevents Death in a Peripheral T Cell Lymphoma Preclinical Mouse Model.ACS Nano2025https://conductscience.org/library/papers/40346022PubMed
40231980Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma.Cancer Biol Med2025https://conductscience.org/library/papers/40231980PubMed
40027134Global research prospects and trends in TFH cells and tumors: a bibliometric analysis.Front Oncol2025https://conductscience.org/library/papers/40027134PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39272178

GET https://conductscience.org/api/papers/v1/39272178/references?page=2